WHO Sounds Alert Over Acute Lack of Obesity Medications

Fewer than a tenth of individuals eligible to benefit from GLP-1 drugs such as Wegovy are able to get them, caution the global health agency as it releases its first recommendations on the therapies.

Given more than one billion individuals worldwide now classified as obese, it is urging more widespread and fairer availability to GLP-1 medication.

According to projections, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.

"The latest guidelines affirms that obesity is a long-term condition that can be treated with comprehensive and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and distribution challenges are key hurdles to broad access to the injections that can assist patients in reducing substantial body mass, notes the agency.

GLP-1 Therapy Supply Crisis

Even in the current most optimistic outlook, the manufacturing of GLP-1 therapies might only reach around 100 million people – fewer than 10% of those who need them, according to the health organization.

The advice urges nations and manufacturers to increase availability, via measures including voluntary licensing.

Exclusive production rights on the active ingredient – the core component of a leading brand – is set to lapse in multiple countries in 2026.

How Obesity Injections Function

GLP-1 drugs replicate a biological compound to delay gastric emptying, suppress the appetite and enhance satiety so users consume fewer calories.

Individuals usually see weight reduction after several weeks of beginning the once-weekly jabs.

Evidence suggests people may regain a significant portion after a year of stopping the medication, when their usual food cravings return.

Being overweight or obese increases your likelihood for experiencing health problems, like diabetes, cardiovascular issues, brain attack, and certain cancers.

Excess weight impacts individuals in every country and was responsible for millions of fatalities worldwide in 2024, per the WHO.